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Abstract
New insights in the study of virus and host biology in the context of viral infection are made 
possible by the development of model systems that faithfully recapitulate the in vivo viral life 
cycle. Standard tissue culture models lack critical emergent properties driven by cellular 
organization and in vivo–like function, whereas animal models suffer from limited susceptibility 
to relevant human viruses and make it difficult to perform detailed molecular manipulation and 
analysis. Tissue engineering techniques may enable virologists to create infection models that 
combine the facile manipulation and readouts of tissue culture with the virus-relevant complexity 
of animal models. Here, we review the state of the art in tissue engineering and describe how 
tissue engineering techniques may alleviate some common shortcomings of existing models of 
viral infection, with a particular emphasis on hepatotropic viruses. We then discuss possible future 
applications of tissue engineering to virology, including current challenges and potential solutions.
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MODELING VIRAL INFECTION
“It is not difficult to find the reason why the virologists have failed where the 
bacteriologists were so successful. They have been severely handicapped by the 
difficulties connected with the cultivation of viruses…. By giving the virologists a 
practicable method for the isolation and study of viruses you relieved them of a 
handicap, burdening them from the birth of their science and placed them for the 
first time on an even footing with other microbe hunters.”
—Sven Gard, in the 1954 Nobel Prize presentation speech
The Advent of Cell Culture and Modern Virology
Viruses are obligate intracellular pathogens; thus, it is not surprising that the field of 
virology continues to advance dramatically on the heels of cell culture technology. Accurate 
recapitulation of viral infection in a laboratory setting is critical for the dissection of virus-
host interactions and ultimately for identification of potential therapeutic targets and 
subsequent drug development. Definition of the conditions under which cells can be 
maintained in culture was pioneered in the late nineteenth and early twentieth centuries (1,2) 
and enabled initial in vitro observation and attenuation of viruses in animal tissue cultures 
(3, 4). In 1949, Enders et al. (5) demonstrated the ability to grow poliomyelitis virus in 
nonneuronal human embryonic tissues, for which they were awarded the 1954 Nobel Prize 
in Physiology or Medicine. The subsequent isolation and serial propagation of the first 
human cell line—HeLa cells—which were shown to be susceptible to poliomyelitis virus 
and other viruses, provided a robust and convenient platform for large-scale virus 
amplification (6).
Where Do 3D Tissue-Engineered Models Fit on the Spectrum?
Since the 1950s, 2D cell culture models have produced a wealth of knowledge regarding the 
mechanisms of infection, and they still constitute the primary platform for viral propagation 
and pathogenesis studies. Despite these advances, standard monolayer or suspension 
cultures, though they are accessible, well characterized, and amenable to large-scale 
experimentation, do not adequately recapitulate the complexity of living organisms. In vivo, 
cells are integrated into higher-order structures, where they receive biochemical and 
mechanical cues via interaction with extracellular matrix (ECM), soluble signals, and other 
cells. The contributions of these components to cell state are pleiotropic and may often 
impact both the cells’ susceptibility and their response to viral infection.
As researchers aim to culture newly discovered viruses and pinpoint cellular factors that 
impact the course of disease, additional systems that bridge the gap between traditional 
monolayer cultures and animal models are required. To this end, tissue engineering (TE) 
may have a significant role in moving virology into the next era of discovery. Owing to 
greater control over various orthogonal parameters, cells in these 2D or 3D systems can 
more accurately capture emergent tissue properties (e.g., multicellular architecture) and 
exhibit altered viability, morphology, differentiation status, proliferation capacity, and gene 
expression profiles, often yielding phenotypes that differ significantly from their 
counterparts in conventional culture. Maintenance of tissue-specific host factors, innate 
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immune function, cell cycle status, and polarity that more closely resemble analogous cells 
in vivo may better support the natural course of viral infection than do cells in standard 
tissue culture, generating viral titers and persistence characteristics more closely resembling 
the in vivo scenario (see Figure 1).
Through the definition of ECM niches from a physical, chemical, and biological 
perspective; the synthesis of biomaterials with controllable properties across many 
dimensions; and the establishment of microtechnological tools to enable precise cellular 
organization, TE has expanded the number and type of models that exhibit emergent 
properties (7, 8). It is possible to independently select the components of the system [cell 
type(s), matrix, etc.] and to define and scale both the geometry and quantity of individual 
models (even allowing for high-throughput applications), which offers advantages over 
laboratory animal models that are not always available, are costly, are more difficult to 
assay, and are even subject to ethical debate. TE models provide a fertile middle ground for 
experimentation. They are discussed in further detail below, along with their application in 
modern virology, specifically with respect to hepatotropic viruses.
TISSUE ENGINEERING: COMPONENTS AND CURRENT STATUS
Whereas isolated primary cells or lines lack access to the native environment that typically 
modulates their phenotype in vivo, TE offers the ability to control interactions between cell 
types of interest and other cells (8, 9), matrix components (10), and soluble growth factors/
cytokines (11), as well as the cells’ exposure to physical forces and defined 3D contexts. 
Here, we briefly review each of these components.
Cell Sources for Tissue Engineering
Because of their robustness in culture and the relative ease of maintaining the viability of 
immortalized cells, cell lines such as HepG2 hepatoma cells have been used to engineer 
some epithelial tissues (13), and human umbilical vein endothelial cells (HUVECs) are often 
used in the TE of vascular constructs (14). Stromal cell lines can also be used to support 
primary or progenitor-derived cells in TE constructs (15). However, because primary cells 
are fully differentiated and exhibit higher levels of tissue-specific functionality than cell 
lines, they are a preferred cell source. For example, engineered tissues have been created 
with primary hepatocytes (16), neurons (17), and cardiomyocytes (18). Additionally, the 
flexibility in the choice of materials and soluble factors means that TE can be used to enable 
phenotypic maintenance of some cell types, such as hepatocytes (19), hepatic stellate cells 
(20), and neurons (17), whereas standard cell culture platforms cannot.
Finally, stem- and progenitor-derived cells are increasingly being used in TE. Though these 
cell types can be challenging to maintain in a differentiated state, and current differentiation 
protocols often yield immature cell types more closely related to fetal than to adult cells, 
they offer the promise of genetically tractable, expandable, and fully functional cells. TE 
strategies to recapitulate developmental niches (21) have resulted in successful early 
examples of several stem cell–derived tissues including liver (23), brain (24), intestine (25), 
heart (26), and vasculature, and numerous efforts to expand and combine these tissue types 
are underway.
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Scaffolding Materials for Tissue Engineering
Biomaterials provide mechanical support and chemical cues to cells in TE scaffolds. Many 
biomaterials have been studied, and the choice of biomaterial depends upon the specifics of 
the fabricated tissue. Natural materials often contain endogenous domains that encourage 
cell attachment and proliferation, and they do not stimulate strong immune responses upon 
implantation, making them promising for transplant applications. Natural TE materials 
include fibrin, which promotes angiogenesis and vascular integration (27); collagen, a 
ubiquitous component of the ECM with numerous integrin-binding motifs (28); hyaluronic 
acid (29); alginate (30); and the basement membrane–mimicking Matrigel (31). However, 
natural biomaterials are less well characterized and are less amenable than synthetic 
materials to engineering and modification.
To alleviate these shortcomings, a wide variety of synthetic polymeric materials have been 
developed for TE applications. These include US Food and Drug Administration (FDA)-
approved materials such as poly(lactic-co-glycolic acid) (PLGA)-based (33) and 
poly(ethylene glycol) (PEG)-based (34, 35) materials, as well as newer classes of polymers 
that exhibit better antifouling properties (36), modularity (37), or stimulus responsiveness 
(38). These materials have mechanical and gel-forming properties that can be tuned over 
wide ranges and have typically been designed to provide a biologically inert background 
upon which bioactive motifs such as RGD can be added (39).
As a way to combine the bioactive properties of natural materials with the modularity and 
control of synthetic materials, tissue engineers have generated many examples of hybrid 
materials, which contain natural and synthetic components that often provide orthogonal 
control or functionality. Gelatin methacrylate, synthesized from collagen, is a photo-cross-
linkable biomaterial used in 3D bioprinting and stereolithography that maintains its base 
material’s cytocompatible properties (40), and numerous hyaluronic acid derivatives have 
been engineered to exhibit photoactivatable or constitutive cross-linking and allow for the 
display of tethered peptides or proteins (29). In a different strategy, Martino et al. (41) 
recently developed a PEG-fibrin hybrid in which minimal fibrinogen fragments are grafted 
onto tunable PEG backbones to impart fibrin’s proangiogenic and growth factor–binding 
properties.
Soluble and Tethered Signaling Factors in Tissue Engineering
In addition to cells of interest and scaffolding materials, TE models commonly incorporate 
growth factors to modulate cell function (11). VEGF (vascular endothelial growth factor) 
and PDGF (platelet-derived growth factor) have been commonly utilized to encourage 
angiogenesis and maturation of engineered vessels and skeletal muscle (42), BMP-2 (bone 
morphogenic protein 2) has been used to encourage bone tissue growth (43), and NGF 
(nerve growth factor) has been used to encourage neuronal growth (44). Unlike in standard 
2D monolayer culture, transport and utilization of growth factors (45), passive sequestration 
by protein binding partners (41), and chemically induced tethering of growth factors (11) 
can all lead to gradient formation and distinct zones in engineered tissues (46) that better 
recapitulate heterogeneous organ microenvironments.
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Other stimuli can also produce spatially distinct signaling effects in engineered tissues. 
Oxygen availability in densely packed tissues varies with distance to a perfused channel, and 
oxygen tension significantly affects numerous cellular pathways (47). Similarly, shear stress 
induced by fluid flow affects endothelial phenotype (48) and affects many epithelial cells 
(49) that are shear protected in vivo. These gradients can be modulated by varying vessel 
density and perfusion rates in constructs under flow, to provide both a physiological 
microenvironment and a platform for continuous sampling of engineered constructs.
Architecture of Tissue-Engineered Constructs
In vivo, tissue microarchitecture is intimately linked to its function; therefore, control over 
tissue architecture has been explored in engineered constructs. The ability to pattern cells 
using engineering techniques has been exploited in 2D engineered cultures. For example, 
cell shape has been examined, and spatially segregated cocultures of different cell types 
have been generated by microcontact printing with adhesive proteins (50).
Cellular patterning has also been extended to TE in 3D in order to control cell spreading and 
movement (17), spatially organize groups of cells (53), and control the production of 
vascular networks (54). Many techniques have been used to accomplish these goals: 
Photolithographic (40) or porosity-generating (55) techniques can modify the overall 
scaffold structure, and orthogonal chemical approaches have been used to pattern proteins 
and mechanical variations into these constructs (56). DNA (57) and shape-templated (58) 
approaches can also be used to hierarchically assemble small cell-laden building blocks into 
larger, multicomponent structures. Recent improvements in 3D printing of biological 
materials have also enabled the direct deposition of cells and matrix in defined 
configurations (59).
TISSUE ENGINEERING ADVANTAGES AND APPLICATIONS FOR MODELS 
OF VIRAL INFECTION
TE models have the potential to bridge the gap between viral infection in standard cell 
culture, which may lack higher-order tissue functions, and infection of animal models, 
which are less experimentally and genetically tractable and may make it difficult to isolate 
responses of interest. Here, we review the benefits of TE specific to the study of viral 
infections.
Advantages of Tissue-Engineered Constructs for Studying Viral Infection
Whereas standard cell culture models of viral infection are limited to single cell types, most 
viral infection in vivo involves multiple cell types. TE approaches have the potential to 
capture this cellular diversity and have been used in the liver, for example, to demonstrate 
the dependence of hepatocyte state on supporting cell types including endothelium (60, 61), 
fibroblasts (61a), and Kupffer cells (62). These interactions are important in hepatitis C virus 
(HCV) infection, as virion binding to liver sinusoidal endothelial cell (LSEC) receptors (63) 
can result in transcriptional changes that directly (through transinfection) and indirectly 
(through LSEC cytokine production) affect HCV infection of hepatocytes (64). Kupffer cell 
activation in HCV also modulates viral progression (65), and the incorporation of these two 
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cell types into a liver-mimicking microenvironment could constitute a more relevant cellular 
milieu for understanding HCV infection in vitro. Hepatitis B virus (HBV) similarly 
modulates innate immune pathways in liver nonparenchymal cells (66) (which affect 
hepatocytes) in a way that engineered coculture systems might capture.
Beyond capturing relevant cell-cell interactions, TE offers avenues to study dynamic 
processes in host-pathogen interactions. Infection-relevant phenotypes such as endothelial 
barrier permeabilization (67) and immune cell trafficking (68) can be incorporated into 
engineered systems. For example, dengue virus (DENV) infection of endothelial cells leads 
to inflammation, increased permeability, and progression to septic shock upon immune cell 
recruitment to the infected endothelial cells (69). Modeling this phenomenon could help to 
predict and treat vascular complications.
The dynamic measurements enabled by TE extend to multicomponent tissues as well, as 
multiple tissue compartments can be fabricated in a spatially controlled manner at the 
microscale or mesoscale by microstructuring materials for cell encapsulation or assembly of 
microtissues containing distinct cell populations (19, 57). Increased control over materials 
chemistry and processing also allows the engineering of interfaces to smoothly connect 
different engineered tissue types (70), which may be important for studying viruses that 
affect multiple tissue compartments. For example, the multistage infection cycle of herpes 
simplex virus (HSV) is difficult to model in standard cell culture (71). By creating spatially 
defined mucosal and neural compartments in a manner amenable to time-lapse imaging and 
analysis, viral latency and reactivation could potentially be studied more directly (72). Even 
within tissues, spatial variation in cellular phenotype can affect viral infection. The cell type 
compartmentalization and positioning afforded by TE techniques may also be of use in 
understanding influenza infection. For example, engineered respiratory tracts could 
potentially be used to conclusively determine sialic acid–linked receptor specificity for avian 
and human viruses (73), and the effect of other important airway components such as the 
respiratory mucus layer (74) could be studied in an experimentally facile system.
Some of the effects detailed above can be adequately captured in animal models of infection. 
However, whereas intravital imaging techniques are improving in capability and 
accessibility, real-time monitoring of cellular and molecular parameters in some deeper 
organs can be difficult (75), and genetic manipulation in these systems requires time-
consuming mouse engineering and breeding. TE couples the ability to generate relevant 
tissue complexity with the ability to easily manipulate input cells and capture biological and 
virological readouts. Cells in TE constructs are easily accessed by growth factors and 
cytokines (11), but they can also be manipulated genetically by lentiviral transduction (76, 
77) or RNA interference (78), either prior to encapsulation or in situ in engineered tissues 
(76, 77). By tethering or trapping the viruses or nucleic acids in scaffold materials, this 
manipulation can also be spatially controlled (78) to target select subsets of cells. Combined 
with reporters easily introduced into encapsulated cells (79), numerous standard imaging 
modalities are available for analyzing TE constructs, including fluorescence tomography or 
multiphoton fluorescence compatible with thick engineered tissues, magnetic resonance, and 
electron microscopy (80). Many of these approaches can be used in real time to provide 
dynamic pictures of viral infection in engineered tissues.
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Some Existing Examples of Tissue Engineering for Studying Viral Infection
Although the application of TE to viral models is still in its infancy, there are several 
existing examples of pathogen infection in engineered tissues. Those pertaining to the liver 
are covered in detail below. Outside of the liver, TE techniques have also been used to 
create an in vitro model of HSV-1 infection that captures latent neuronal infection and 
reactivation (72). In this model, a latently infected combined neuronal and dermal layer 
resides next to an epidermal layer at an air-water interface. Latent HSV DNA can be 
reactivated upon UV exposure, providing an in vitro reactivation model to complement 
animal studies. HSV has also been studied in the context of oncolytic virus therapy in TE 
tumor models: Viral infection and spread depend upon ECM degradation in brain tumors 
(81) and melanoma models (81a). Dynamic culture systems (82) can support microorganism 
growth as well, with a commensal bacterium modulating epithelial barrier integrity in a TE 
microfluidic device (83). Although this initial effort did not incorporate viruses, it could be 
adapted to studying enterovirus infection in this relevant intestinal model. Recent efforts to 
engineer in vitro bone marrow analogs may also aid the study of viral infection, as 
appropriate TE systems mimicking bone marrow microenvironments (84) have been shown 
to promote hematopoietic stem or progenitor cell differentiation, even resulting in B 
lymphocyte differentiation and influenza-specific antibody formation upon inoculation with 
the virus (84). These efforts highlight the potential of TE to provide more relevant viral 
model systems in the future.
HEPATOTROPIC VIRUS INFECTION IN MODELS WITH EMERGENT 
PROPERTIES
Hepatotropic viruses are globally distributed and cause both acute [e.g., hepatitis A virus 
(HAV) and hepatitis E virus (HEV)] and chronic (e.g., HBV and HCV) infection, leading to 
liver fibrosis, cirrhosis, hepatocellular carcinoma, and, ultimately, end-stage liver disease 
requiring liver transplantation (85–88). Although functional HAV, HBV, and, recently, HEV 
vaccines are available along with direct-acting antivirals targeting HBV or HCV, these 
pathogens remain prevalent in the human population. Furthermore, they continue to be a 
challenge to study in the laboratory setting due to a paucity of robust model systems that 
mimic clinical aspects of disease.
Current Limitations in the Study of Hepatotropic Viruses
Attempts to culture these viruses in vitro and in vivo have been limited by their restricted 
host range and hepatotropism. Although HEV has been found in various species in addition 
to humans (reviewed in 89), HAV infects only humans and nonhuman primate species, and 
only humans, chimpanzees, and tree shrews (Tupaia belangeri) are naturally susceptible to 
HCV and HBV (reviewed in 90). The requirement for liver-enriched factors such as the 
microRNA miR-122 for HCV (91) and transcription factors (e.g., HNF4α, PPARα, RXRα), 
some of which are liver enriched, for HBV (92) further restricts the cell type that will permit 
viral replication. In the absence of cell culture–adaptive mutations, slow viral replication and 
protein synthesis kinetics also remain an issue—in the case of wild-type HAV, antigen 
accumulation and particle production take weeks (93).
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Further, although an efficient cell culture system was established for HCV with the isolation 
of a genotype (gt) 2a virus from a Japanese patient with fulminant hepatitis C (JFH-1) (94), 
this virus is genetically diverse, including six major genotypes and numerous subtypes that 
differ in their geographic distribution, response to antiviral therapy, and disease association 
(reviewed in 95). Currently, the study of genotype-specific phenotypes is restricted to 
replicons (96, 97), HCV pseudoparticles (98), and intergenotypic JFH-1-based recombinant 
viruses (99).
For HEV, cell culture systems exist for gt3 (100) and gt4 (101)—the two zoonotic genotypes 
of the four identified to date that infect humans (87). Still, the efficiency of HEV growth in 
cell culture is poor. Further, whereas cDNA clones of other HEV strains have been 
generated and shown to be infectious in either nonhuman primates (102) or pigs (103), in 
vitro studies are limited due to a lack of virus spread in cultured cells. Similarly, for HBV, 
hepatoma cells that replicate and assemble the virus (e.g., HepG2) have been identified 
(104), but these cells do not permit HBV entry without additional manipulation (105). 
Researchers therefore resort to systems that feature integrated HBV genomes or delivery of 
HBV DNA to cells via transfection.
Existing models of hepatotropic viral infection rely predominantly upon human hepatoma– 
or hepatocellular carcinoma–derived cell lines. The aberrant proliferative potential and 
polarity of these lines, combined with their dysfunctional drug metabolism and innate 
immune axis, can obscure important biology and make it critical to study viral infection in 
the authentic host cell (primary human hepatocytes). Additionally, both viral and host 
genetics have profound impacts on the outcome of infection, such as the influence of 
polymorphisms in the IL28B locus on spontaneous clearance of HCV and response to 
treatment (106, 107) or the highly varied success in achieving infection in primary 
hepatocytes of different human donors. Thus, there is great interest in establishing both in 
vitro and in vivo platforms for all of these viruses with pan-genotypic permissiveness, 
particularly those that feature the natural target cell of the virus and reflect the genetic 
diversity of the infected population (e.g., primary human hepatocytes, pluripotent stem cell– 
derived hepatocyte-like cells).
Polarization and Differentiation of Immortalized Cells
Manipulation of immortalized cells toward a more polarized or differentiated state has 
resulted in more permissive systems for hepatotropic viral infection and has yielded unique 
insights into viral entry mechanisms. Early evidence of productive HCV infection in culture 
came from the use of a human hepatocellular carcinoma–derived line (FLC4) cultured in 3D 
radial-flow bioreactors (108). More recently, Aly and coworkers demonstrated that HCV 
replication was increased in immortalized primary hepatocytes cultured in a 3D 
thermoreversible gelatin polymer (TGP) system (109) and that viral particle production was 
achieved upon challenge with HCV gt1b and gt2a (110) when these cells were cultured in a 
3D hollow fiber system (111). Like the TGP system, the hollow fiber reactor is smaller scale 
than the radial-flow bioreactor, allowing easy access to both medium and cells for 
virological assessment. In a standard cell culture model, HepaRG cells were also shown to 
be permissive for gt3a serum-derived HCV during the proliferation stage, and once the cells 
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were fully differentiated, they were able to replicate the virus and produce infectious 
particles, indicating that properties of both immature and mature hepatocytes may be 
beneficial for culture of HCV in vitro (112).
Additional polarized models, including HepG2 cells ectopically expressing miR-122 and 
CD81 (a receptor for the virus) and Huh-7/Huh-7.5 cells exposed to dimethyl sulfoxide 
(DMSO), in Matrigel, or in rotating wall vessels, have been shown to be permissive for 
HCV (113–115). These systems have demonstrated unique viral phenotypes including 
infectious particle production from a dicistronic gt1b HCV genome (116) and a shift in viral 
particle density compared with 2D-produced virus, suggesting assembly or association with 
host proteins and/or lipids may be altered in 3D (117). The HCV result has also been 
extended to 3D engineered tissues with HCV-permissive cell lines (117a). Notably, the 
addition of human serum (1–2%) to the medium in several systems had a beneficial impact
—it promoted an increase in extracellular HCV RNA production in human adult hepatocytes 
(118) and more rapid viral penetration followed by more consistent detection of HCV RNA 
after inoculation of HepaRG cells with human serum-derived HCV (112). Steenbergen and 
colleagues (119) also reported growth arrest and increased expression of albumin, lipid 
metabolism–related genes, and cell-cell contact proteins, as well as HCV receptors, in 
Huh-7.5 cells exposed to human serum. These cells produced higher-titer, lower-density 
HCV, suggesting that serum factors impact cellular and viral phenotype.
Cell context has also recently been considered with the goal of increasing viral yields in 
HEV infection systems. Berto and colleagues (120) demonstrated detectable HEV RNA in 
the supernatants of PLC/PRF/5 cells cultivated in a rotating wall vessel but not in 2D 
cultures inoculated in parallel, and Rogée et al. (121) also demonstrated HEV RNA in 
supernatants of Matrigel-embedded HepaRG and PICM-19 cells (bipotent human and 
porcine lines, respectively, that differentiate into biliary or hepatocyte-like cells) cultured 
with murine embryonic fibroblasts. Direct comparison of RNA levels produced in these 
systems with those produced in primary hepatocytes or cell lines in standard culture is 
challenging given the differences in the source, titer, and quantity of inoculums used. 
However, these 3D systems may abrogate the requirement for high-titer inoculation to 
launch infection and may enable unique insight into infection pathways—particularly entry 
and egress.
For example, vectorial entry and release of HAV was shown to differ between enterocyte-
derived, polarized Caco-2 cells on porous membrane supports (apical) (122) and a subclone 
of HepG2 cells (basolateral) (123), consistent with the expected route of exposure to HAV 
during transmission. For HCV, the entry process involves two tight junction proteins 
[claudin-1 (124) and occludin (125)], highlighting the importance of polarized cell models in 
defining precise entry mechanisms (126). Expression, organization, and dynamics of these 
receptors are altered upon polarization (127, 128), and several studies have noted reduced 
susceptibility to infection following polarization (127), suggesting cell junctions also act as 
physical barriers. Disruption of tight junctions may promote viral transmission (129), and 
the use of cellular proteins localized to this region may facilitate cell-cell spread (130).
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HBV infection also depends on cell differentiation status. HepG2 cells normally support 
HBV replication and virus release following transfection with HBV DNA (104). Treating 
these cells with DMSO renders them permissive for HBV entry (105). Similarly, the 
differentiation state of HepaRG cells—mediated by DMSO and corticoid treatment— 
correlates with HBV susceptibility (131). The expression of the bile acid pump NTCP 
(sodium taurocholate cotransporting polypeptide)—a newly identified receptor for HBV— 
increases upon differentiation of HepaRG cells and decreases in primary tupaia hepatocytes 
after plating (132). Interestingly, DMSO treatment of either HepG2 or Huh-7 cells 
overexpressing NTCP robustly increases infection efficiency in those HBV-permissive cells 
(133). Collectively, these observations link cellular differentiation, entry factor expression, 
and viral susceptibility. HBV gene expression and replication are also linked to cellular 
differentiation status induced by culturing cells on ECM and treating with DMSO or 
dexamethasone (131). This is likely due to the increased expression of required host 
transcription factors, such as HNF4α and its regulator HNF1α, which control the HBV 
transcription machinery (134). TE techniques can modulate cell polarization and 
differentiation status through their control over cell-cell and cell-matrix interactions and 
soluble signals, and this modulation can strongly affect viral infectivity in these models.
Primary Cell Culture Models
Although differentiated, polarized cells yield more accurate insight into entry events, the 
host response to infection still differs in immortalized cells (compared with authentic host 
cells) due to their abnormal proliferation, dysregulated gene expression, and aberrant 
signaling. Thus, primary cell models may be useful for certain aspects of host-pathogen 
biology. The application of TE concepts to both primary human hepatocytes and induced 
pluripotent stem cell (iPSC)-derived cells has made these model systems more tractable, 
enabling in vitro interrogation of viral infection across cells with different genetic 
backgrounds.
Although primary hepatocytes are the principal target cells of hepatotropic viruses, and thus 
the most physiologically relevant model system, infection of these cells in vitro has been a 
challenge. Once dissociated from their native hepatic microenvironment, primary 
hepatocytes lose their polyhedral morphology, exhibit a decline in liver-specific function as 
determined by albumin secretion and cytochrome P-450 enzymatic activity, and become less 
susceptible to viral infection (136). Multiple groups have challenged primary hepatocytes 
[human fetal (137, 138) and adult (139, 140), chimpanzee (141), nonhuman primate (142), 
and tupaia (143, 144)] with tissue culture–derived virus or sera from infected HCV, HEV, or 
HBV patients. Results suggest that inoculation with high viral load is necessary but not 
sufficient and that amplification is typically low level and fluctuating.
Similar to induction of a differentiated state in immortalized cells, maintenance of this state 
in primary hepatocytes in vitro is critical for initial susceptibility to infection and efficient 
viral replication. Early reports noted increased yield and duration of HBV infection in the 
presence of DMSO or PEG (145); more recently, groups have employed nonparenchymal 
cells to promote hepatocyte function and subsequently viral infection in vitro (146). LDLR 
(low-density lipoprotein receptor) and EGFR (epidermal growth factor receptor), two host 
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cofactors for HCV entry (147, 148), were more highly expressed when hepatocytes were 
cultured with LSECs on a single layer of collagen or in spheroid form on Matrigel (149). 
Further, spherical hepatocyte masses, initially cultured in the presence of preattached stellate 
cells, efficiently replicated HCV clones of gt1a, gt1b, and gt2a (150). Similarly, long-term 
cultures of primary human fetal hepatocytes were developed by plating a hepatic cell 
mixture at low density, allowing outgrowth of nonparenchymal cells and formation of 
hepatic islands that were subsequently cultured under DMSO-containing conditions to 
maintain characteristic hepatocytic features; these cultures were susceptible to HBV 
infection for up to 10 weeks in culture (151). In 3D engineered tissues, Bcl-2-transduced 
HUVECs have been used to modulate fetal hepatocyte phenotype and permit HCV 
replication (151a).
Adding microscale architecture to the concept of coculture systems, Ploss et al. (152) 
generated miniaturized hepatocyte islands of optimized dimensions, surrounded by 
supportive 3T3-J2 murine embryonic fibroblast cells, termed micropatterned cocultures 
(MPCCs). Unlike collagen gel sandwiches, Matrigel substratum, or random cocultures, 
MPCCs were able to sustain infection of a luciferase-expressing HCVcc. Infection 
frequency in this system was low with both HCVcc and plasma or sera from infected 
patients, but the authors demonstrated the potential application of this model as a 
physiological system for preclinical screening of antiviral therapeutics. Beyond HCV 
(152,153), this model also supports infection with malaria (154) and HBV (unpublished 
data). Toward recapitulation of complete tissue architecture, human adult ex vivo liver slice 
methods were recently adapted to virology. Common challenges of this system include poor 
viability and inherent variability (154a); however, Lagaye et al. (155) demonstrated 
productive infection of JFH-1 or JFH-1-based chimeric viruses as well as a gt1b primary 
isolate in cultures that remained viable for 10 days.
In theory, primary human hepatocytes provide the opportunity to correlate host genotype 
and viral phenotype under controlled experimental conditions. In practice, this has been 
difficult to achieve with statistical significance given the limited number of donors available 
and the inability to prescreen or select cells from patients of a particular genotype of interest. 
Alternatively, pluripotent stem cells have the capacity for infinite self-renewal and can be 
genetically altered at the pluripotent stage before differentiation into hepatocyte-like cells, 
enabling the introduction of a desired host phenotype and the parallel production of 
isogeneic controls. Importantly, human embryonic stem cell (hESC)- and iPSC-derived 
hepatocyte-like cells supported the complete HCV life cycle, evidenced by entry and 
replication in HCV-pseudotyped virus and subgenomic replicon assays, respectively (156), 
and by challenge with HCVcc (157–159) and gt1b- and gt1a-containing patient sera 
(HCVser) (whereas Huh-7.5 cells were not permissive for HCVser). In addition, short 
hairpin RNA–mediated knockdown of cyclophilin A or PI4KIIIa rendered these cells 
resistant to HCV, providing proof of concept for the use of genetic manipulation in these 
cells to interrogate host-pathogen interactions (157). Still, human hepatocytes derived from 
pluripotent stem cells or directly from fibroblasts via transdifferentiation are still 
functionally immature and exhibit a very different transcriptional profile from that of 
primary adult human hepatocytes (159a). Recent approaches to mature these cells using 
chemical (159b), genetic (159c), or combination approaches (159d) have yielded more 
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adult-like phenotypes, which will be important for ensuring that the host-pathogen 
interactions explored in these systems are indicative of mature responses to infection.
Expansion of In Vivo Platforms
The restricted species tropism of hepatotropic viruses has led to the development of 
transgenic and humanized mouse models (e.g., uPA+/+-SCID, FAH−/−Fag2−/−Il2rg−/−, and 
AFC8) to launch infection of HBV and HCV in vivo (reviewed in 162, 163). Although 
chimeric human liver mouse models—in which genetic injury of mouse hepatocytes permits 
repopulation with and expansion of transplanted human hepatocytes—allow completion of 
the entire viral life cycle and have been instrumental in establishing rodent models of HBV 
and HCV, they are restricted by low breeding efficiency, high mortality, and the need for 
consistent, robust engraftment of human hepatocytes to achieve HCV viremia. This, along 
with variable chimerism, has led to difficulty in cost-effectively generating large cohorts of 
mice for viral challenge.
In attempt to alleviate these issues, efforts to generate additional mouse models have 
focused on supplementation of critical nonhomologous host factors (164), suppression of 
innate immunity (165), or viral adaptation (166). Alternatively, implantation of TE models 
featuring human cells into immunodeficient mice can stabilize cell phenotype, minimize 
engraftment variability, and serve as a platform to assess drug metabolism and toxicity in 
vivo (15). This work can be extended to 3D engineered tissue models of HCV, malaria, and 
HBV infection in primary hepatocytes, as a way to create ectopic human livers (15) 
permissive to infection in a small-animal model. These ectopic tissues may also provide an 
alternative to liver injury–based mouse models, allowing researchers to circumnavigate host 
barriers to infection in vivo.
FUTURE APPLICATIONS OF TISSUE ENGINEERING TO THE STUDY OF 
VIRAL INFECTION
Improved Control over Model System Inputs
To date, identification of TE model systems that promote desired cellular and virological 
phenotypes has largely been empirical. Rapid optimization of these models will benefit from 
platforms that allow systematic perturbations of the microenvironment that may result in 
prolonged cellular viability or expression of host proteins that are critical for viral 
propagation. Toward this goal, ECM arrays have been employed to determine optimal 
substrates for maintenance of liver-specific function in rat hepatocytes and for murine 
embryonic stem cell differentiation (167) and to test the combinatorial effects of ECM and 
soluble factors on cell fate (168). High-throughput platforms have also more recently been 
described for 3D constructs (169, 170). Such systems hold potential for drug toxicity 
screens, cell-ECM interaction studies, and investigation of cellular phenotypes that depend 
on cellular localization within 3D tissues, similar to the in vivo case. These systems provide 
methods for the identification of microenvironmental cues that yield desired cellular 
properties, and can be used in concert with genome-editing tools, including CRISPR-Cas 
(clustered, regularly interspaced short palindromic repeat–CRISPR-associated) (171) and 
TALEN (transcription activator–like effector nuclease) (172) approaches, which enable 
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more precise control over the cell-autonomous aspects as well. By combining TE model 
systems with iPSC technology, researchers can now, in principle, generate personalized 
models of viral infection and follow up on clinical data or studies on host factors with 
significant clinical correlations identified through human genetic studies.
Capturing Cellular and Organ-Level Complexity
Tissue engineers exercise a great level of control over the types and positions of cells and 
scaffold materials. The use of TE to study viral infection can further be expanded by 
integrating dynamic reporters of cellular function and infection and establishing platforms 
for selective analysis of cellular subsets within engineered tissues. Fluorescent reporters for 
infection monitoring can be engineered by modifying either virus or host proteins (153), and 
these can be used in parallel with reporters of host pathways such as IRF3 (interferon 
regulatory factor 3) (173) or NFκB (nuclear factor κB) (79) to track infection spreading and 
responses in real time at unprecedented resolution. Cellular responses to infection can also 
modify local microenvironments through ECM remodeling and through local cytokine 
release, which can be tracked in real time by tethering reporters of protease activity (174) or 
biomolecule accumulation (175) into engineered tissues.
Integrating viral and cell state reporters into TE constructs may also aid in selecting 
subpopulations of interest for further analysis at the transcriptomic and proteomic level. 
Laser capture microdissection (176) can be used to selectively isolate infected cells from 2D 
engineered tissues (177), and a newly developed photo-uncaging approach can be used to 
isolate RNA from specific cells in 3D tissues (178). Additionally, the ability to selectively 
degrade certain scaffolding hydrogels with light (179) offers an orthogonal approach for 
accessing specific cells within engineered tissues.
Extending TE to the development of organ-on-a-chip systems will enable greater 
understanding of multiorgan interactions during viral infections. Advances in microfluidic 
on-chip cell culture (82) and assembly of microscale engineered tissue segments (57, 180) 
could enable multiorgan circuits consisting of cells in connected, functional organ modules 
that more accurately recapitulate in vivo biochemical, metabolic, and genetic activity. 
Pertinent to the development of viral models, these multiorgan systems could include 
engineered lymphoid components that serve as a dynamic reservoir for circulating immune 
cells (181) and constitute part of the host response to all viruses. The interconnections 
between organ modules can also be efficiently endothelialized to enable the study of 
endothelial responses either upon primary infection (63, 182–184) or secondary to systemic 
cytokine release, and the existence of multiple organ modules also offers the potential to 
predict off-target effects of new proposed antiviral therapies.
Dynamic Systems
Matrix remodeling, cell migration, chemical gradients, and mechanical forces (such as the 
laminar shear stress imposed by blood flow or phasic stress produced by breathing) 
represent dynamic aspects of living systems. Chemical gradients and mechanical forces 
modulate cell function (185, 186) and can impact the course of infection (187, 188); 
microfluidic devices represent versatile, miniaturized, and automatable platforms to generate 
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these gradients and forces in vitro. The use of microfluidics in virology is in its infancy, but 
examples illustrate its potential for viral infection dynamics studies (189), viral 
quantification or diagnostics (190), imaging (191), and single-particle assays (192) as well 
as screen-based approaches to identify novel host-pathogen interactions (193).
CURRENT CHALLENGES AND NECESSARY BREAKTHROUGHS
The adoption of TE approaches to model viral infection will depend on making tissue 
engineering platforms robust and accessible and capturing as much relevant biology as 
possible. Below we review some major remaining challenges along this path.
Standardization of Tissue-Engineered Platforms
Although standard tissue culture approaches often lack key host functions, they are still 
widely used because of their experimental simplicity and robustness. Tissue engineers can 
similarly focus on standardization to make TE more accessible for studying viral infection. 
On the materials side, numerous approaches can reduce TE scaffold variability. First, large-
batch synthesis or modification of scaffold materials can reduce variability in chemical 
modification percentages between synthesis runs. This problem can also be mitigated by 
using newly developed, high-efficiency orthogonal chemical reactions (194) for scaffold 
modification and cross-linking and by using controlled polymerization reactions for 
synthetic materials (195). Standardized sterilization or aseptic techniques for TE scaffold 
manipulation can also prevent the contamination that sometimes occurs in these more 
complex culture formats.
Toward this end, lessons can be learned from existing standardized TE platforms. MPCCs 
are used at an industrial scale for screening drugs for human liver toxicity (61a,196), and 
AggreWell plates can reliably produce defined-size cellular aggregates for stem cell culture 
and TE (197). Recently, a scalable platform for 3D pluripotent stem cell culture was also 
reported that uses a commercially available thermoresponsive material (38). As evidenced 
by these examples, focusing on simplicity in structure, material choice, and processing can 
aid in standardization of TE formats.
Transport and Data Collection in Tissue-Engineered Constructs
Unlike in standard monolayer cell culture, cells in TE constructs are subject to nutrient 
transport constraints due to the 3D nature of the culture format and impeded transport 
through materials with small pore sizes. In general, cells in TE constructs must be within 
100–200 μm of a perfused channel to receive adequate levels of nutrients; strategies for 
vascularization in TE are extensively covered in recent reviews (e.g., 198). When using TE 
models to study viral infection, the vascularization requirement may be even more acute, as 
virions must be able to access host cells within the construct. Virions may traverse small-
pore PEG hydrogels to host cells (117a), but this process is inefficient across long distances. 
Additionally, for viruses that utilize entry receptors of specific polarity, appropriate cell 
positioning and polarization must be maintained in TE constructs to facilitate viral entry. 
Transport is relevant to viral infection even outside of virion access, because the oxygen 
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tension gradient generated by cell-dense TE constructs can affect viral replication through 
HIF-1α (hypoxia-inducible factor 1α)-dependent mechanisms (199).
Several methods exist to provide adequate transport within TE platforms, either through 
prefabrication of vascular channels using sacrificial materials (54), through directed cell 
seeding via microengineering (60) and bioprinting (59), or through stimulation of self-
organizing endothelialized vascular networks (200, 201). For in vitro models of viral 
infection, new parallelizable bioprinting approaches (202) are favorable because they 
combine reproducible channel formation with the scalability to adequately power studies. 
Printing with multiple materials and cell types in defined positions (59) should enable 
patterned vascular network formation next to virally permissive parenchymal tissue 
components. In conjunction with adequate vascular access to tissue compartments, the 
continued development of orthogonal fluorescent (79, 153) and secreted (203, 204) reporters 
of viral and cell state will enable multiplexed, real-time analysis of viral infection in TE 
constructs.
Sustaining Cell Phenotype in Tissue-Engineered Constructs
Although cell lines are generally amenable to manipulation, the development of more 
physiologically relevant viral models requires the use of more fragile primary and stem- or 
progenitor-derived cells. The cell-cell signal density inherent in 3D culture systems can 
promote the phenotypic maintenance and function of some primary (15, 61) and progenitor 
(205) cells, but previously developed protocols for cell maintenance or directed 
differentiation of progenitor cells in 2D (206) may not directly translate to TE systems. 
These protocols can be performed prior to cell isolation and TE scaffold incorporation, but 
isolation from the native microenvironment often diminishes tissue-specific functions of 
differentiated cells. Further, in multicompartment TE models, the optimal culture medium 
formulation and other signals may vary from compartment to compartment.
Several approaches may be used to circumvent these problems. By optimizing protocols for 
long-term 3D culture in formats that allow atraumatic cell harvest, 2D culture steps can be 
eliminated altogether for TE with differentiated stem-derived cells (38). Development of 3D 
protocols for in situ directed differentiation of progenitors will be useful, aided by the 
inherent advantages of 3D differentiation for some lineages (207), the vast choice of cell 
fate–instructive scaffold materials (21, 37, 208), increased control over biomolecule 
presentation and valency in TE constructs (7), and new approaches for high-throughput 
arrayed 3D culture formats (209). Additionally, the precise control over mixing in 
microfluidic systems may allow spatial gradients in nutrient composition to control 
differentiation status and phenotypic maintenance (45, 46), enabling cross talk between 
organ modules while preventing off-target effects of culture medium additives.
CONCLUSIONS
The study of virology depends on adequate model systems to accurately capture the various 
stages of viral infection, from entry to replication to egress. Compared with standard cell 
culture techniques on one end, and animal models on the other, TE has the potential to 
recapitulate relevant higher-order interactions while preserving the ability to readily 
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manipulate distinct components of the system. Continued advancements in TE will more 
readily allow the precise positioning of cells, matrix, and soluble factors, and interactions 
between these components, in a way that captures emergent properties important in viral 
infection. For example, TE approaches should enable the study of viral infection and spread 
in multiorgan models, the elucidation of host-pathogen interactions in authentic host cells, 
and the development of medium- and high-throughput analyses of viral replication in more 
physiological contexts.
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KEY TERMS AND DEFINITIONS
DMSO dimethyl sulfoxide
ECM extracellular matrix
gt genotype (of a given virus)
HAV hepatitis A virus
HBV hepatitis B virus
HCV hepatitis C virus
HEV hepatitis E virus
LSEC liver sinusoidal endothelial cell
Microfluidics systems (sometimes containing cells) in which small volumes of 
fluids are manipulated and guided through architectures created 
using engineering lithography tools
MPCC micropatterned coculture
Organ-on-a-chip 
system
multiple engineered tissues integrated into a microfluidic system 
that enables fluid and soluble factor exchange between 
compartments
PEG poly(ethylene glycol)
Scaffolding materials natural materials (e.g., ECM components) or synthetic polymers 
used to provide mechanical support and biochemical cues to cells 
in engineered tissues Tissue engineering (TE): combining cells, 
scaffolding materials, and soluble factors in a defined 
architecture to create a living tissue mimic
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SUMMARY POINTS
1. Cell-cell and cell–extracellular matrix interactions and soluble signals impact 
cellular phenotype and thus susceptibility and response to viral infection.
2. Tissue-engineered models capture relevant biological complexity (e.g., cellular 
diversity, cell-cell interactions, chemical gradients) and are easier to miniaturize, 
multiplex, manipulate, and assay than in vivo models.
3. The application of tissue-engineered models in modern virology is in its infancy.
4. The initial implementation of tissue engineering concepts in the study of 
hepatotropic viruses has yielded systems that are more permissive for viral 
infection and has allowed unique insight into certain aspects of the viral life 
cycle.
5. Tissue engineering has enabled maintenance of primary cell function in vitro 
and thus may offer the opportunity to correlate host genotype and viral 
phenotype.
6. Generation and transplantation of 3D tissue-engineered models into small 
animals may expand current in vivo platforms and allow researchers to 
circumnavigate existing technical limitations and host barriers to infection.
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FUTURE ISSUES
1. High-throughput screening platforms to identify specific extracellular matrix 
and soluble factor combinations that promote cellular and virological 
phenotypes will enable optimization of current and novel tissue-engineered 
models.
2. Implementation of genome-editing tools and dynamic reporters of cellular 
function and infection will permit the development of personalized models of 
viral infection with real-time system monitoring capabilities.
3. Integration of multiple engineered tissues (e.g., organ-on-a-chip systems) and 
dynamic systems that allow cross talk between cellular compartments and 
recapitulate biological forces (e.g., microfluidic platforms) will allow 
interrogation of viral infection in models that capture additional aspects of 
relevant in vivo complexity.
4. Optimization of tissue engineering protocols to allow incorporation of primary 
cells and stem- or progenitor-derived cells into 3D models will expand the types 
of culture systems that feature physiologically relevant cell types with diverse 
host genetic backgrounds.
5. Modulation of biomaterials or formation of vascular channels within tissue-
engineered constructs will improve nutrient transport and virion access to cells 
within 3D models.
6. The standardization of methodology and the use of widely accessible reagents in 
the construction of tissue-engineered platforms will make these systems more 
accessible to virologists.
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Figure 1. 
Tissue engineering (TE) approaches to recapitulate the complexity of the in vivo 
environment. (a) Schematic overview of tissue engineering approaches. Standard tissue 
culture consists of monocultures in monolayers. Tissues in vivo are made up of various cell 
types organized in specific 3D structures. TE approaches aim to model the emergent 
properties and architecture of the in vivo environment using combinations of relevant cell 
types, extracellular matrix proteins or mimics, and soluble signals (e.g., cytokines), 
organized into specific patterns using engineering tools, to promote cellular health in vitro or 
function upon implantation in vivo (e.g., vascularization). Because TE models replicate 
aspects of the in vivo environment, they may enhance virus permissiveness and result in 
more authentic host-virus interactions. TE models assembled with induced pluripotent stem 
cell (iPSC)-derived cells could also give rise to personalized models with defined and 
manipulable host genetics. (b) Chart comparing TE approaches with other in vitro and in 
vivo platforms. TE models bridge the simplicity of tissue culture with the completeness of 
animal models, while maintaining the capacity for easy manipulation and interrogation of 
cellular and viral inputs.
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